Palatin Technologies, Inc. (NYSE Amex: PTN) announced that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD)... ![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FUK77rDxRQEzt_8XkNrmyuK0n7ps%2F0%2Fdi&hash=52c63ef9cd74ad43111d9c3e27aeab2c)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FUK77rDxRQEzt_8XkNrmyuK0n7ps%2F1%2Fdi&hash=607402f795270d99dfc20fc947047b1c)
More...
More...